Asia stocks dither ahead of Fed meeting; Japan Q3 GDP in focus
Investing.com - Cantor Fitzgerald has reiterated its Overweight rating and $15.00 price target on Cabaletta Bio Inc. (NASDAQ:CABA), maintaining its positive outlook on the clinical-stage biotechnology company. The stock has shown remarkable momentum, gaining 16.8% in the past week and 161.47% over the last six months, according to InvestingPro data.
The price target represents significant upside potential from the current trading price of Cabaletta Bio shares, which focuses on developing treatments for patients with autoimmune diseases. With a market capitalization of $260.68 million and strong liquidity position evidenced by a current ratio of 4.78, the company maintains a solid financial foundation for its development programs.
Cantor Fitzgerald derived its price target from a discounted cash flow (DCF) analysis through 2031, applying a premium 13% discount rate that reflects development and competitive risks, along with a 4% terminal growth rate.
The firm’s valuation model specifically includes contributions from CABA-201, Cabaletta’s CD19 CAR-T therapy being developed for various B-cell mediated autoimmune diseases.
The maintained Overweight rating suggests Cantor Fitzgerald expects Cabaletta Bio to outperform the average total return of the stocks in the analyst’s coverage universe over the next 12-18 months. The company’s next earnings report is scheduled for November 12, 2025, which will provide crucial updates on its development progress.
In other recent news, Cabaletta Bio Inc. has been the subject of several key developments. The company recently raised $100 million, extending its cash runway into the second half of 2026. This capital raise led to share dilution, prompting Guggenheim to lower its price target from $25 to $15 while maintaining a Buy rating. Similarly, Jefferies adjusted its price target from $28 to $14, also maintaining a Buy rating, and described Cabaletta as a leader in cell therapy for autoimmune diseases.
Jefferies resumed coverage of Cabaletta Bio with a Buy rating and a $14 price target after the company presented data from its RESET-PV clinical trial at the European Society of Gene and Cell Therapy. Cantor Fitzgerald reiterated an Overweight rating with a $15 price target, highlighting a New England Journal of Medicine correspondence about a patient treated with autologous CD19 CAR-T cell therapy. These developments reflect the ongoing interest and analysis of Cabaletta Bio from various research firms.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.